A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Br… (NCT07067138) | Clinical Trial Compass
RecruitingNot Applicable
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
United States175 participantsStarted 2026-02-23
Plain-language summary
Background:
Breast cancer is the most common cancer in US women. There are different types of breast cancers; some are aggressive and difficult to treat. Researchers want to know if an algorithm (ENLIGHT) can help choose approved drugs that will treat these cancers more effectively.
Objective:
To test whether ENLIGHT can find better treatments for aggressive breast cancers.
Eligibility:
People aged 18 years and older with triple-negative or endocrine therapy resistant breast cancer; the cancer must have either failed to respond to treatment or come back after treatment.
Design:
Participants will be screened. A sample of tissue taken from the tumor will be tested using ENLIGHT as well as another method (TruSight Oncology 500).
Participants will be assigned to 1 of 3 groups based on the algorithm search results:
Group 1: No drug option was recommended. Participants will continue with their standard treatment with their local doctors.
Group 2: A drug already approved for the participant's disease was recommended, but the participant has not yet received it. These results will be sent to the participant's local doctors. Participants may return to the NIH if their disease gets worse after using the suggested drugs.
Group 3: A drug approved for other uses was recommended. Participants will be treated with the recommended drugs at the NIH; their care will be managed by an NIH doctor. They will continue to receive treatment as long as the drugs are helping them. They will have follow-up visits for 2 years after treatment ends.
Participants who are not treated at the NIH will be contacted for a check on their health every 3 months for 2 years.
Who can participate
Age range18 Years – 120 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participants must have a histologically confirmed diagnosis of metastatic breast cancer. Note: Pathology testing outside NIH will be accepted for eligibility purposes.
✓. Participant tumor subtypes will be enrolled as follows:
✓. Participants must have been treated with at least one (1) line of systemic therapy after diagnosis of metastatic disease, have progressive disease or adverse events requiring discontinuation of their current regimen, and must not be able to transition to another approved systemic therapy shown to improve overall survival.
✓Participants with HR+ disease must be deemed refractory to endocrine therapy per their clinical team, with concordance by study team.
✓. Participants must have measurable disease per RECIST v1.1. Note: Palliative radiotherapy to site(s) of disease may be completed during screening as long as disease outside of the planned sites of radiation is available for response assessment.
✓. Archival tumor (preserved via FFPE) must be available from a biopsy performed within the past 6 months. The timeframe of 6 months is required to optimize reliability of ENLIGHT results. It is assumed that a participant has had no more than one (1) line of systemic treatment since the last biopsy. Participants who have had multiple intervening lines of therapy since biopsy was obtained will be reviewed by the study team to determine if another biopsy may be needed. Note: If archival tissue is not available within that timeframe, tissue from the next scheduled biopsy can be sent to NIH for testing. If it is not possible for a biopsy to be scheduled, the study team will evaluate the possibility of a biopsy being performed at the NIH for enrollment purposes.
What they're measuring
1
Part A: To assess the feasibility of using the ENLIGHT algorithm to match heavily pretreated participants with metastatic breast cancer to off-label therapies
Timeframe: Assessed after the Reporting Visit of the 20th participant to the study, and to be completed before Part B
2
Part B: (If feasibility lead-in met) To assess the objective response rate (ORR) of participants with advanced breast cancer using treatment recommended by the ENLIGHT algorithm
Timeframe: Every 2 cycles until progression of disease, completion of treatment, or 2 years after treatment initiation (whichever comes first)
✓. ECOG performance status \<2 (Karnofsky \>60%)
Exclusion criteria
✕. Participants in active visceral crisis, symptomatic brain metastases requiring local therapy, or active leptomeningeal disease given the time required for testing and therapy selection.
✕. Participants with uncontrolled intercurrent illness evaluated by physical exam and chemistries or situations that would limit compliance with study requirements, interpretation of results or that could increase risk to the participant.
✕. Participants with the following active cardiac conditions: symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia (per medical record).
✕. Participants with lung disease requiring continuous oxygen supplementation.
✕. Participants with decompensated cirrhosis and/or end-stage kidney disease on dialysis.
✕. Participants with positive serum or urine beta-HCG pregnancy test performed at screening.
✕. Participants who are unable to provide tissue specimens of sufficient quality for use in this study. Quality of DNA and RNA is determined during screening. This may be due to issues with biopsy sample collection, inadequate RNA extraction, or quality control failure. Participants may be re-screened if initial specimens are not adequate, if they are amenable to re-biopsy, and additional site(s) of disease for adequate re-sampling are available.